Vor Biopharma Inc. (NYSE: VOR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $12.00 price target on the stock.
MediumReport
Vor Biopharma Inc. (NYSE: VOR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $12.00 price target on the stock.
Vor Biopharma Inc. (NYSE: VOR) had its price target lowered by analysts at Stifel Nicolaus from $15.00 to $12.00. They now have a "buy" rating on the stock.
MediumReport
Vor Biopharma Inc. (NYSE: VOR) had its price target lowered by analysts at Stifel Nicolaus from $15.00 to $12.00. They now have a "buy" rating on the stock.
Vor Biopharma Inc. (NYSE: VOR) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $15.00 price target on the stock, down previously from $17.00.
MediumReport
Vor Biopharma Inc. (NYSE: VOR) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $15.00 price target on the stock, down previously from $17.00.
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: